anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the field of biological pharmacy and provides a monoclonal antibody for resisting cell surface ectopic expression. The amino acid sequence of a light chain variable region at the Fab fragment antigen-binding site of an antibody molecule is shown as SEQ ID NO:2, and the amino acid sequence of a heavy chain variable region is shown as SEQ ID NO:4. The invention also provides application of the monoclonal antibody in preparation of medicaments for treating and preventing digestive tract tumors or digestive tract tumor metastasis. The invention also provides a detection kit and medicinal composition containing the monoclonal antibody. The invention also provides a preparation method of the monoclonal antibody. A series of in vivo and in vitro tests prove that the purified and degermed monoclonal antibody has high affinity for PALP and/or IALP antigen for resisting extracellular ectopic expression of tumor cells and has a biological activating function of inhibiting growth and migration of tumor cells.
The invention discloses a chimeric compound for degrading cyclophilin A and a preparation method and application thereof. The structural formula of the chimeric compound is shown as a formula I. The compound shown in the formula I can be used for preventing and/or treating CypA mediated diseases, such as CypA mediated inflammation, autoimmune diseases and/or tumors. The invention also providesA pharmaceutical composition comprising as active ingredient a compound of formula i and at least one pharmaceutically acceptable carrier, excipient and/or diluent. The compound shown in the formula I can degrade CypA protein in a targeted mode, and therefore the compound can be used for preparing medicines for treating related diseases such as inflammation, autoimmune diseases and tumors. The compound shown in the formula I has obvious inhibition function on virus-induced pneumonia, rheumatoid arthritis and lung cancer cell migration and infiltration. Formula I.
Porogen containing calcium phosphate cement compositions are provided. Aspects of the cement compositions include a dry calcium phosphate reactant component, a setting fluid component and a porogen component. The porogen component includes at least first and second porogens having different pore forming profiles. Aspects of the invention include combining the cement components to produce a settable composition. Aspects of the invention further include the settable compositions themselves as well as kits for preparing the same. Methods and compositions as described herein find use in a variety of applications, including hard tissue repair applications.
Cohort 2 (CA-008 10 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
The 35 participants accepted Er:YAG laser treatment for Abnormal Frenum Attachment. Each participant was collected their data including history records, abnormal position check, photo, cutting, pain index check, return visit check after three, five and seven days. by researchers.
A single session of Botox (Botulinum toxin A) injection was performed. 50 IU was administered bilaterally by intramuscular injection: 30 IU within the masseter muscles and 20 IU within the anterior temporalis muscles.
1,162,742. Steroids. SHIONOGI & CO. Ltd. 26 April, 1967, No. 19248/67. Heading C2U. A novel 2α,3α-epithio-5α-androstane derivative having an alkyl group at 7α, 7#-, or 8#- position having the general formula wherein R represents an alkyl group containing at most 4 carbon atoms; X represents an oxygen atom, a ketal group or in which R<SP>1</SP> represents a hydrogen atom, an alkyl group containing at most 6 carbon atoms, and an alkenyl group containing at most 6 carbon atoms or an alkynyl group containing at most 6 carbon atoms; R<SP>11</SP> represents a hydrogen atom, a hydrocarbon carboxylic acyl group containing at most 13 carbon atoms or a 1- alkoxy cycloalkyl group containing at most 10 carbon atoms; the ripple mark represents the α or # configuration obtained by reacting a compound represented by the formula wherein X and R are as defined above, Y represents a hydroxyl group, a halogen atom, a hydrocarbon carboxylic acyloxy group containing at most 8 carbon atoms, an alkane sulphonyloxy group containing at most 4 carbon atoms or an arylsulphonyloxy group containing at most 7 carbon atoms which may be substituted by an inert group; Z represents a cyano group or an acyl group containing at most 8 carbon atoms which may have thiocarbonyl group, with a base in an inert solvent to obtain the desired compound if desired by subsequent conversion of the 17-substituent within the definition of X. Such conversion may comprise reducing or reacting with an organometallic compound of the 17-keto compound, or the etherification or esterification of the 17- hydroxy compound. Pharmaceutical compositions containing the above compounds and having anti-estrogenic, anti-uterotropic, estrogenic, implantation inhibition myogenic and androgenic activities are administered enterally or parenterally.
The wait-list group will not participate in the MBSR course within 4 weeks of their first testing visit. They will wait 8-16 weeks and come on for a second testing visit. After their data is collected they will be offered an MBSR course to take.
Pregnant women who have presented with signs and symptoms of threatened preterm labour (e.g. ruptured membranes, contractions, bleeding), at or after 24 weeks gestation, n=50.
Management of mild and moderate knee osteoarthritis is curated to each specific patient and their needs, their quality of life, and desired goals. Weight loss is advised for overweight and obese patients. All patients should attempt extended-duration exercise/physical therapy and realignment therapy. If these conservative lifestyle modifications fail to reduce pain, topical and oral non-steroidal anti-inflammatories are indicated. Escalation of care from here is controversial. Some clinicians opt for adjunctive treatments such as intra-articular injection of steroids or viscosupplementation. Unfortunately, pain alleviation from intra-articular steroids is short-lasting and a recent meta-analysis demonstrated no significant difference between intra-articular hyaluronic acid injection and placebo injection. Finally, weak opioids are an option for patients who continue to have pain despite all the aforementioned treatment measures. Joint replacement is reserved for patients with severe osteoarthritis.

Patients who fail conservative, medical management pose a challenge to clinicians. For decades, there have been no interventions available to these patients between the controversial intra-articular hyaluronic acid injection and joint replacement. Interventional radiology (IR) may provide one possible solution. Geniculate artery embolization (GAE) is a minimally-invasive procedure that has historically been performed for patients with recurrent hemarthrosis. It was recently applied to patients with moderate osteoarthritis refractory to maximal medical management. Several studies have been performed and have found that GAE is safe and improves pain.
Anastrozole 1 mg PO daily and Erlotinib starting dose 75 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Erlotinib found.
FIELD: medicine. SUBSTANCE: desired are vitamin D analogs of formula   wherein Q is C 1 -C 8  hydrocarbylene biradical, R is C 1 -C 6  hydrocarbide. Hydrocarbide (hydrocarbylene) is radical (biradical) resulting from removing 1(2) hydrogen atoms from unbranched, branched or cyclic, saturated or unsaturated hydrocarbon or in which two R groups taken together with carbon atom carrying hydroxyl group form C 3 -C 8  carbocyclic ring. Also described is method of preparing thereof and also are methods of preparing thereof and method of preparing intermediate products. Compounds have immunomodulating and antiflammatory effect and also show high activity in inducing differentiation and inhibition undesirable proliferation of cell including skin cells and cancer cells. EFFECT: improved properties of the vitamin D analogs. 10 cl, 17 ex, 2 tbl
INTRODUCTION: Therapeutic plasma exchange (TPE), an effective method to eliminate harmful soluble mediators associated with tissue injury, serves as a crucial intervention for systemic rheumatologic diseases (SRDs). However, its value in critically ill SRDs remains uncertain. This retrospective study aims to evaluate the efficacy of TPE in SRDs.
METHODS: Critically ill SRD patients admitted to the department of intensive care unit of a large tertiary hospital receiving TPE from January 2011 to December 2019 were included.
RESULTS: A total of 91 critically ill SRD patients received TPE were enrolled. Their mean age was 47.67 ± 16.35 years with a female predominance (n = 68). Significant decrease in SOFA score post-TPE treatment was observed (p < 0.05). There were no TPE-related fatalities. Improvement was observed in 64 (70.32%) patients.
CONCLUSION: This study shows favorable clinical outcomes. TPE may be an acceptable treatment option for critically ill SRD patients.
INTRODUCTION: Obesity has tripled since 1975 and affects health across many domains. Increasing body mass index increases the risk to the obese subject of many non-communicable diseases. The study evaluated the perceptive, aerodynamic, and acoustic parameters that characterize the voice of the obese population.
METHODOLOGY: Eighty adult subjects (40 participants in each obese and control group) aged 18-50 years were enrolled. The perceptual voice analysis was performed using the Consensus Auditory Perceptual Evaluation of Voice. The aerodynamic and acoustic voice analyses were performed using the MIR Spiro lab instrument and Doctor's Speech software. A digital stopwatch was also used to measure maximum phonation time.
RESULTS: Statistical analysis revealed a significant difference (P-value <0.05 and t value >2) between two groups on acoustic parameters, specifically Normalized noise energy and fundamental frequency tremor (F0 tremor). Normalized noise energy and fundamental frequency tremor were greater in the obese group. Moreover, maximum phonation time and expiratory reserve volume were significantly reduced in the obese group.
DISCUSSION AND CONCLUSION: Results of the present study showed poor voice quality and reduced expiratory reserve volume in obese individuals. This could be credited to the adverse effects of accrued adipose on the functioning of the laryngeal and respiratory systems. Increasing body mass index escalates the risk to the obese subjects of many non-communicable diseases.
BACKGROUND: Excessive gestational weight gain, especially among women with gestational diabetes, is associated with several adverse perinatal outcomes. Our study aimed to analyse the impact of the use of pedometers to supervise physical activity on maternal health and the obstetric outcomes of pregnant women with obesity and early gestational diabetes.
METHODS: 124 pregnant patients were enrolled in the presented research.
INCLUSION CRITERIA: singleton pregnancy, age > 18 years, gestational diabetes diagnosed in the first half of pregnancy (< 20th week of pregnancy), obesity according to the American Endocrine Society criteria. Each patient was advised to take at least 5000 steps daily. Patients were randomly assigned to pedometers (N = 62), and were recommended to monitor daily the number of steps. The group without pedometers (N = 62) was not observed. Visit (V1) was scheduled between the 28th and 32nd gestational week (GW), and visit (V2) occurred between the 37th and 39th GW. Anthropometric measurements and blood samples were collected from all patients at each appointment. Foetal and maternal outcomes were analysed at the end of the study.
RESULTS: In the group supervised by pedometers, there were significantly fewer newborns with macrosomia (p = 0,03). Only 45% of patients satisfied the recommended physical activity guidelines. Patients who walked more than 5000 steps per day had significantly higher body weight at baseline (p = 0,005), but weight gain was significantly lower than in the group that did not exceed 5000 steps per day (p < 0,001). The perinatal outcome in the group of patients performing more than 5000 steps did not demonstrate significant differences with when compared to less active group. ROC curve for weight gain above the guidelines indicated a statistically substantial cut-off point for this group at the level of 4210 steps/day (p = 0.00001).
CONCLUSIONS: Monitoring the activity of pregnant patients with gestational diabetes and obesity by pedometers did not have a significantly impact on their metabolic control and weight gain. However, it contributed to less macrosomia. Furthermore, physical activity over 5,000 steps per day positively affects weight loss, as well as contributes to improved obstetric and neonatal outcomes.
This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
INTRODUCTION AND OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters the nasal cavity, penetrates the nasal epithelial cells through the interaction of its spike protein with the host cell receptor angiotensin-converting enzyme 2 (ACE2) and then triggers a cytokine storm. We aimed to assess the biocompatibility of fullerenol nanoparticles C60(OH)40 and ectoine, and to document their effect on the protection of primary human nasal epithelial cells (HNEpCs) against the effects of interaction with the fragment of virus - spike protein. This preliminary research is the first step towards the construction of a intranasal medical device with a protective, mechanical function against SARS-CoV-2 similar to that of personal protective equipment (eg masks).
METHODS: We used HNEpCs and the full-length spike protein from SARS-CoV-2 to mimic the first stage of virus infection. We assessed cell viability with the XTT assay and a spectrophotometer. May-Grünwald Giemsa and periodic acid-Schiff staining served to evaluate HNEpC morphology. We assessed reactive oxygen species (ROS) production by using 2',7'-dichlorofluorescin diacetate and commercial kit. Finally, we employed reverse transcription polymerase chain reaction, Western blotting and confocal microscopy to determine the expression of angiotensin-converting enzyme 2 (ACE2) and inflammatory cytokines.
RESULTS: There was normal morphology and unchanged viability of HNEpCs after incubation with 10 mg/L C60(OH)40, 0.2% ectoine or their composite for 24 h. The spike protein exerted cytotoxicity via ROS production. Preincubation with the composite protected HNEpCs against the interaction between the spike protein and the host membrane and prevented the production of key cytokines characteristic of severe coronavirus disease 2019, including interleukin 6 and 8, monocyte chemotactic protein 1 and 2, tissue inhibitor of metalloproteinases 2 and macrophage colony-stimulating factor.
CONCLUSION: In the future, the combination of fullerenol and ectoine may be used to prevent viral infections as an intranasal medical device for people with reduced immunity and damaged mucous membrane.
Recent research suggests that the benefits of combined physical-cognitive training may be greater than either physical or cognitive training alone. Nevertheless, this synergistic effect has been demonstrated mainly in cognitively intact older adults. Studies examining the effects of combined physical-cognitive training in older adults with MCI are scarce and show mixed results. Moreover, few studies have determined the effects of the combined training on peripheral brain-derived neurotrophic factor (BDNF) and mitochondrial function. Thus, the present study aims to investigate the effects of combined physical-cognitive training on cognitive function as well as peripheral BDNF level and mitochondrial function of individuals with MCI. The present study will provide insight into the interplay among the training program, peripheral BDNF concentration, mitochondrial function, and cognitive function. Importantly, the findings will have clinical implication regarding the training program that is feasible and effective in improving cognitive function of older adults with MCI which ultimately will have great impact on public health as this population is at high risk of progression to AD.
In the placebo group, patients received Sham Reiki. Sham Reiki was administered to cancer patients for four consecutive days at specified times. During this procedure, while the patient was in the supine position, Sham Reiki practitioner's hands were placed approximately two to three centimeters above the chakra regions of the patient, covering the seven chakra areas as well as the areas experiencing pain. The application lasted a total of 25-30 minutes. Silence was maintained in the patient's room during the intervention.
Long-term oxygen therapy (LTOT) prescribed 15 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen \> 8 kPa in accordance with current routine practice and management guidelines.
A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes an active agent effective to increase T3 concentration in the lung of the subject and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The active agent can include a deiodinase inhibitor, a thyroid hormone mimetic, or a thyroid hormone analog. In some embodiments, the composition can include an additional active agent. The compositions can be used to treat lung inflammation. In some embodiments, the compositions also can be used to treat pulmonary edema. The compositions can be administered to a subject by direct instillation to the pulmonary tract or inhalation directly to the pulmonary tract.
OBJECTIVE: A hypo-enhancement of the liver in contrast-enhanced ultrasound (CEUS), pathologic one-minute hepatic enhancement (pOMHE), was recently observed in 70% of allogeneic hematopoietic stem cell transplantation patients with a high-risk profile for veno-occlusive disease (VOD). Whether pOMHE was a pre-clinical sign of VOD or an unspecific feature of liver damage secondary to intensive chemotherapy is unclear.
METHODS: To investigate this, we studied CEUS patterns in patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (auto-HSCT) or intensive induction therapy (IT) for the treatment of acute leukemia. From April 2020 to May 2021, patients undergoing auto-HSCT (n = 20) or acute leukemia patients prior to IT (n = 20) were included. All patients underwent a B-mode ultrasound and CEUS of the liver and spleen before treatment (d0) and on day 10 (d10) after therapy start. The one-minute hepatic enhancement was quantified. An optical density of liver enhancement less than 90% compared with the spleen was considered pathologic (pOMHE). Clinical and laboratory parameters used to assess a drug-induced liver injury (DILI) were documented.
RESULTS: The OMHE was normal (d0 and d10) in 36 (90%) patients. After IT, 2 of 20 patients had a pOMHE. A DILI grade IV was diagnosed in one case and hyperfibrinolysis in the second case. In 2 of 20 (5%) auto-HSCT patients a pOMHE was observed at d10 without clinical symptoms.
CONCLUSION: Chemotherapy-induced effects are not the cause of a pathologic liver enhancement. In contrast, severe DILI or hyperfibrinolysis can be associated with pOMHE.
Pregnant patients who are undergoing inpatient betamethasone therapy as part of their clinical care will be eligible for the study. Once the clinical team and patients have agreed to pursue betamethasone therapy, the patients' treating physician or nurse will inquire if the patient is interested in participating in our study protocol. Those patients who are interested in participation will be consented by either a member of the treatment team or the study team. Prior to receiving the first betamethasone dose, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. For those patients who will be receiving a scheduled course of betamethasone, the sensor may be inserted up to 24 hours prior to the betamethasone administration. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for the duration of her hospitalization or for up to 7 days total, whichever time period is shorter. For those patients who are diabetic, they will receive normal finger stick blood glucose (FSBG) monitoring and insulin therapy as determined by their treating physicians. Those patients who are not diabetic will need to have 2 FSBG checks each day to correlate with the device. Abnormal values will be reported to the patients' treating physician and addressed by the treating physician. Prior to being discharged from the hospital, the patient will have the device removed. The patient will otherwise be treated routinely. We will record baseline demographic information and medical history from each of the women. We will also record information from the neonates' newborn medical records.
The package for dental composition, comprises a primary deformable envelope (1), an internal envelope, a partition for dividing internal envelope from primary envelope in two compartments containing two components to be mixed in a form of powder and liquid, an internal space of the primary envelope, and a third compartment for a third component to participate in the dental composition. The primary envelope is itself divided after a mixing to form a paste and to deliver a single dose of the dental composition constituted by the paste. The package for dental composition, comprises a primary deformable envelope (1), an internal envelope, a partition for dividing internal envelope from primary envelope in two compartments containing two components to be mixed in a form of powder and liquid, an internal space of the primary envelope, and a third compartment for a third component to participate in the dental composition. The primary envelope is itself divided after a mixing to form a paste and to deliver a single dose of the dental composition constituted by the paste. The partition is a thin film (30) defining a closed packet that contains the liquid. The packet is connected at the wall of the envelope and is free inside the envelope. The primary envelope is defined by two peripherally welded waterproof sheets (12, 14) according to a transverse welding defining the partition and having an adhesion force appreciably lower than that of the peripheral welding. The transverse welding differs from the peripheral welding by a filler material, welding technique and/or welding parameters.